Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Total Current Liabilities: 2020-2024

Historic Total Current Liabilities for Janux Therapeutics (JANX) over the last 5 years, with Dec 2024 value amounting to $17.5 million.

  • Janux Therapeutics' Total Current Liabilities rose 62.06% to $27.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.8 million, marking a year-over-year increase of 62.06%. This contributed to the annual value of $17.5 million for FY2024, which is 33.96% up from last year.
  • Janux Therapeutics' Total Current Liabilities amounted to $17.5 million in FY2024, which was up 33.96% from $13.0 million recorded in FY2023.
  • In the past 5 years, Janux Therapeutics' Total Current Liabilities registered a high of $17.5 million during FY2024, and its lowest value of $3.2 million during FY2020.
  • Moreover, its 3-year median value for Total Current Liabilities was $16.5 million (2022), whereas its average is $15.7 million.
  • Per our database at Business Quant, Janux Therapeutics' Total Current Liabilities soared by 302.29% in 2021 and then fell by 21.05% in 2023.
  • Over the past 5 years, Janux Therapeutics' Total Current Liabilities (Yearly) stood at $3.2 million in 2020, then skyrocketed by 302.29% to $12.8 million in 2021, then increased by 28.99% to $16.5 million in 2022, then dropped by 21.05% to $13.0 million in 2023, then spiked by 33.96% to $17.5 million in 2024.